Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Viveve Medical Inc VIVE

Viveve Medical, Inc. designs, develops, manufactures and markets a platform medical technology, Cryogen-cooled Monopolar RadioFrequency (CMRF). The Company’s CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, which collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI). In the United States, the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis. The Viveve System is cleared for marketing in approximately 48 countries throughout the world, including North America, Asia Pacific, Europe, the Middle East and Latin America countries. The Company’s wholly owned subsidiaries include Viveve, Inc. and Viveve BV.


GREY:VIVE - Post by User

Post by dmacdon Mar 12, 2019 11:17am
92 Views
Post# 29473062

Liberate International for SUI

Liberate International for SUIResults expected around August 2019 for the international study with 99 participants.Positive results will be a catalyst for the SP barring any requirements for additonal follow ups. I am quite optimistic since Viveve would not be wasting cash on parallel tests if there was not high confidence that the outcome will be positive.

It is possible for an early release of partial results although I am not sure if they set up the analytical committee to do that. This would be a risk of not having a core position if you are trying to time the rally. Certainly the lack of news is positive since if there were negative outcomes then the program would have been halted. 

The results for the International test will basically be the precursor for the US testing, and while the results there will be more comprehensive the outcome can be projected with more confidence. Meanwhile clearances can be put into place and now there will be more than double the revenue potential for clinics since there may be a stigma for the non-SUI application whereas everyone can relate empathetically to the SUI appilcation. I believe these two applications may leverage one another so 1 +1 = 3 but time will tell. 

It will also be an easier sell for the health care providers to pay for the procedure. We need some good news in August since gaining profitability will not be possible while these tests are being performed. 
<< Previous
Bullboard Posts
Next >>